StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $0.15 | $0.14 | -6.44% | 5.1M |
| 05-14 | $0.15 | $0.14 | -8.45% | 2.2M |
| 05-15 | $0.13 | $0.14 | +3.85% | 4.2M |
| 05-18 | $0.14 | $0.13 | -7.94% | 4.6M |
| 05-19 | $0.13 | $0.12 | -5.64% | 1.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
SANGAMO THERAPEUTICS INC
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.44M | $39.55M | $25.32M | $24.74M |
Operating Income | $-31.95M | $-121.24M | $-83.04M | $-47.48M |
Net Income | $-31.00M | $-122.93M | $-85.51M | $-50.58M |
EPS (Diluted) | $-0.08 | $-0.44 | $-0.33 | $-0.21 |
Total Assets | $59.97M | $59.74M | $88.64M | $97.56M |
Total Liabilities | $78.92M | $74.01M | $82.40M | $77.96M |
Cash & Equivalents | $27.59M | $20.95M | $29.62M | $38.34M |
Free Cash Flow OCF − CapEx | $-19.30M | $-97.31M | $-72.89M | $-44.33M |
Shares Outstanding | 389.62M | 350.69M | 260.80M | 238.71M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.